DDInter1642 DDInter979
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma.[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.
Isatuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Isatuximab {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Isatuximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Isatuximab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Isatuximab may lead to a major life threatening interaction when taken with Golimumab
Isatuximab may lead to a major life threatening interaction when taken with Upadacitinib